The Seraph 100 ® Microbind Affinity Blood Filter Does Not Alter Levels of Circulating or Mucosal Antibodies in Critical COVID-19 Patients

• Published in: Antibodies (Basel) 2024-08, Vol.13 (3), p.65
• Main Authors: Conner, Tonia L, Vir, Pooja, Laing, Eric D, Stewart, Ian J, Mitre, Edward, Pratt, Kathleen P
• Format: Article
• Language: English
• Subjects: Affinity; Antibodies; Blood; Blood circulation; Blood levels; Clinical outcomes; COVID-19; Enrollments; Hemoperfusion; Heparin; Immunoglobulin A; Immunoglobulin G; Measurement; Mucosa; mucosal; Nucleocapsids; Observational studies; Physiological aspects; Review boards; SARS-CoV-2; Seraph 100; Severe acute respiratory syndrome coronavirus 2; Viral antibodies
• ISSN: 2073-4468; 2073-4468
• DOI: 10.3390/antib13030065

PURIFY-OBS-1 is an observational study evaluating the safety and efficacy of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) use for COVID-19 patients with respiratory failure admitted to the intensive care unit (ICU). The Seraph 100 is a hemoperfusion device containing heparin-coated beads that can bind to, and reduce levels of, some circulating pathogens and inflammatory molecules. This study evaluated whether treatment with the Seraph 100 affected circulating and mucosal antibody levels in critically ill COVID-19 subjects. SARS-CoV-2 anti-spike and anti-nucleocapsid IgG and IgA levels in serum were evaluated at enrollment and on days 1, 4, 7, and 28 after Seraph 100 application, while anti-spike and nucleocapsid IgG, IgA, and secretory IgA levels in tracheal aspirates were evaluated at enrollment and on days 1, 2, 3, 7, and 28. Serum samples were also collected from the pre- and post-filter lines at 1 and 4 h following Seraph 100 application to evaluate the direct impact of the filter on circulating antibody levels. Treatment with the Seraph 100 did not alter the levels of circulating or mucosal antibodies in critically ill COVID-19 subjects admitted to the ICU.